Novel lipopeptide antibiotics from paenibacillus strains for fusarium head blight control

Overview

This research focuses on discovering novel lipopeptide antibiotic compounds from two rhizosphere-associated Paenibacillus bacterial strains that exhibit potent biocontrol activity against Fusarium graminearum, the primary pathogen responsible for Fusarium head blight (FHB) in cereal crops. Current microbial approaches to FHB management primarily rely on inducing systemic resistance in host plants, with limited exploration of novel active molecular structures produced by beneficial microbes. This work addresses that gap by identifying new lipopeptide antibiotics and developing optimized active compositions for crop protection applications.

Technical specifications

Key research components:

• Discovery platform: Two Paenibacillus sp. strains isolated from rhizosphere environments demonstrating antifungal activity at 50 ug/mL concentration in vitro
• Biosynthetic gene cluster analysis: Strain-1 contains 16 biosynthetic gene clusters (6 NRPS, 3 NRPS-PKS, 4 RiPPs); Strain-2 contains 17 gene clusters including one NRPS-type cluster with low gene similarity suggesting potential for fully novel peptide antibiotics
• Compound identification: UPLC-MS/MS molecular network analysis of fermentation product organic extracts used to characterize novel metabolites
• Validation approach: Greenhouse pot trials to assess disease suppression and deoxynivalenol (DON mycotoxin) accumulation reduction
• Formulation development: Active ingredient combinations designed for crop fungicide applications
• Mode of action studies: Investigation of bioactive compound mechanisms against FHB pathogens

Technology readiness level

This research is currently at an early-to-mid stage of development. Laboratory validation has confirmed the biocontrol potential of the two Paenibacillus strains and identified promising biosynthetic gene clusters for novel lipopeptide production. Future validation plans include greenhouse pot trials for disease suppression assessment, identification and characterization of new antifungal compounds, formulation development with fungicide molecule groups, and mode of action investigations. The technology requires further compound purification, structural elucidation, formulation optimization, and field validation before commercial readiness.